Cutaneous rash as a surrogate marker of time to tumor progression (TTP) with erlotinib in previously treated advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Cedres Perez, S. [1 ]
Prat, A. [1 ]
Felip, E. [1 ]
Peralta, S. [1 ]
Perez, J. [1 ]
del Campo, J. [1 ]
Sala, G. [1 ]
Andreu, J. [1 ]
Pallisa, E. [1 ]
Baselga, J. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19125
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED ERLOTINIB/GEFITINIB WHO FAILED PREVIOUS CHEMOTHERAPY
    Madolangan, Jamaluddin
    Andarini, Sita Laksmi
    Hudoyo, Achmad
    RESPIROLOGY, 2014, 19 : 165 - 165
  • [42] Disease stabilization (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib (E) or gefitinib (G)
    Pronzato, P.
    Loprevite, M.
    Brianti, A.
    Defferrari, C.
    Catania, G.
    Grossi, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] PTPRF expression as prognostic/predictive marker for treatment with erlotinib in non-small cell lung cancer (NSCLC)?
    Klughammer, Barbara
    Bordogna, Walter
    Delmar, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (30)
  • [44] Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small cell lung cancer (NSCLC)
    Grossi, F.
    Brianti, A.
    Defferrari, C.
    Loprevite, M.
    Catania, G.
    Pronzato, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Phase I and pharmacodynamic study of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in previously treated advanced non-small cell lung cancer (NSCLC)
    Gerber, David E.
    Skelton, Rachael
    Dong, Ying
    Loudat, Laurin
    Dowell, Jonathan
    Boothman, David A.
    Sarode, Venetia
    Zhang, Wei
    Xie, Yang
    Gazdar, Adi
    Frenkel, Eugene P.
    Schiller, Joan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Randomized phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Garon, E. B.
    Dubinett, S. M.
    Hosmer, W.
    Reckamp, K. L.
    Kabbinavar, F. F.
    Goodglick, L.
    Marquez-Garban, D. C.
    Stabile, L. P.
    Siegfried, J.
    Pietras, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Randomized, multicenter phase II study of erlotinib (E) or E plus fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).
    Garon, E. B.
    Dubinett, S. M.
    Kabbinavar, F. F.
    Reckamp, K. L.
    Marquez-Garban, D. C.
    Goodglick, L.
    Sharma, S.
    Stabile, L. P.
    Siegfried, J.
    Pietras, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Cutaneous complications of erlotinib in the treatment of non-small cell lung cancer
    Preda, V.
    Mann, S.
    Lee, S.
    HONG KONG JOURNAL OF DERMATOLOGY & VENEREOLOGY, 2008, 16 (03): : 133 - 141
  • [49] A phase II trial of denileukin diftitox in patients with previously treated advanced non-small cell lung cancer (NSCLC).
    Lewis, MAG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 653S - 653S
  • [50] Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
    Wang, Z.
    Han, X.
    Guo, J.
    Zhu, D.
    Zhang, X.
    Tang, X.
    Meng, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S1400 - S1400
12345